-- Company to begin limited market release in Europe in June

Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE 
Mark for the EXALT(TM) Model B Single-Use Bronchoscope, a single-use device 
designed for bedside procedures in the intensive care unit, operating room and 
bronchoscopy suite. Limited market release of the device is expected to 
commence in Europe in the coming weeks.

Logo - https://mma.prnewswire.com/media/329537/Boston_Scientific_Logo.jpg  

The EXALT Model B Bronchoscope will be offered in three sizes - slim, regular 
and large - to allow for use in a wide variety of bronchoscopy procedures such 
as secretion management, airway intubation, percutaneous tracheostomy, double 
lumen endotracheal tube placement and biopsies. 

"As single-use bronchoscopes are relatively new, continued innovation is 
necessary to ensure physicians can achieve direct and precise visualization 
into a patient's lungs and air passages," said Prof. Dr. Kaid Darwiche, head of 
the Department of Interventional Pneumology at Ruhrlandklinik in Germany. "The 
EXALT Model B Bronchoscope provides clear, crisp imaging and high-powered 
suction - both of which are critical to successfully identify any abnormalities 
in the patient's airway."

Throughout Europe, more than 1.5 million procedures involving a bronchoscope 
are performed each year.(i) While the potential for infection due to 
reprocessing of reusable scopes is low, there have been reports of 
scope-associated contaminations and post-procedure infections.(ii) To combat 
this risk, a recent position statement from the European Society of 
Gastrointestinal Endoscopy (ESGE) and the European Society of Gastroenterology 
Nurses and Associates (ESGENA) strongly recommended the use of single-use 
endoscopic accessories whenever possible.(iii)

"Single-use scopes are emerging as the preference for many physicians due to 
their ability to eliminate the risk of scope-related infection that may result 
from ineffective reprocessing while also increasing operational efficiencies in 
the hospital setting," said Dave Pierce, executive vice president and president 
of MedSurg and president of Endoscopy, Boston Scientific. "Innovation is 
central to our mission, and the EXALT Model B Bronchoscope is designed to 
provide physicians with the high-quality functionality and feel of a reusable 
scope, while addressing heightened patient safety needs and improving 
efficiency." 

The EXALT Model B Bronchoscope is the latest device in the Boston Scientific 
single-use imaging portfolio. For decades, the company has worked closely with 
physicians to continuously innovate and develop single-use technologies within 
the gastrointestinal, pancreaticobiliary, surgical, urological and airway 
spaces to advance patient care, including the EXALT(TM) Model D Single-Use 
Duodenoscope ( 
https://c212.net/c/link/?t=0&l=en&o=3169680-1&h=3647331172&u=https%3A%2F%2Fwww.bostonscientific.com%2Fen-EU%2Fproducts%2Fsingle-use-scopes%2Fexalt-model-d.html&a=EXALT%E2%84%A2+Model+D+Single-Use+Duodenoscope 
), LithoVue(TM) Digital Flexible Ureteroscope ( 
https://c212.net/c/link/?t=0&l=en&o=3169680-1&h=114963467&u=https%3A%2F%2Fwww.bostonscientific.com%2Fen-EU%2Fproducts%2FUreteroscopes%2FLithoVue.html&a=LithoVue%E2%84%A2+Digital+Flexible+Ureteroscope 
), SpyGlass(TM) DS Direct Visualization System ( 
https://c212.net/c/link/?t=0&l=en&o=3169680-1&h=895977728&u=https%3A%2F%2Fwww.bostonscientific.com%2Fen-EU%2Fproducts%2Fdirect-visualization-systems%2Fspyglass-ds-direct-visualization-system.html&a=SpyGlass%E2%84%A2+DS+Direct+Visualization+System 
) and SpyGlass(TM) Discover Digital Catheter ( 
https://c212.net/c/link/?t=0&l=en&o=3169680-1&h=4141527817&u=https%3A%2F%2Fwww.bostonscientific.com%2Fen-EU%2Fproducts%2Fdirect-visualization-systems%2Fspyglass-discover-digital-catheter.html&a=SpyGlass%E2%84%A2+Discover+Digital+Catheter 
).

Please visit 
www.bostonscientific.com/en-EU/medical-specialties/pulmonology/EXALT-B.html for 
more information about the EXALT Model B Bronchoscope. 

The EXALT Model B Bronchoscope is not available for use or sale in the United 
States.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that 
improve the health of patients around the world. As a global medical technology 
leader for more than 40 years, we advance science for life by providing a broad 
range of high performance solutions that address unmet patient needs and reduce 
the cost of healthcare. For more information, visit www.bostonscientific.com 
and connect on Twitter ( 
https://c212.net/c/link/?t=0&l=en&o=3169680-1&h=3619337495&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2934865-1%26h%3D1272181342%26u%3Dhttp%253A%252F%252Ftwitter.com%252Fbostonsci%26a%3DTwitter&a=Twitter 
) and Facebook ( 
https://c212.net/c/link/?t=0&l=en&o=3169680-1&h=3090652692&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2934865-1%26h%3D1548985104%26u%3Dhttp%253A%252F%252Fwww.facebook.com%252Fbostonscientific%26a%3DFacebook&a=Facebook 
).

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of 
Section 27A of the Securities Act of 1933 and Section 21E of the Securities 
Exchange Act of 1934.  Forward-looking statements may be identified by words 
like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" 
and similar words.  These forward-looking statements are based on our beliefs, 
assumptions and estimates using information available to us at the time and are 
not intended to be guarantees of future events or performance.  These 
forward-looking statements include, among other things, statements regarding 
our business plans, clinical trials, product launches and product performance 
and impact.  If our underlying assumptions turn out to be incorrect, or if 
certain risks or uncertainties materialize, actual results could vary 
materially from the expectations and projections expressed or implied by our 
forward-looking statements.  These factors, in some cases, have affected and in 
the future (together with other factors) could affect our ability to implement 
our business strategy and may cause actual results to differ materially from 
those contemplated by the statements expressed in this press release.  As a 
result, readers are cautioned not to place undue reliance on any of our 
forward-looking statements. 

Factors that may cause such differences include, among other things: future 
economic, competitive, reimbursement and regulatory conditions; new product 
introductions; demographic trends; intellectual property; litigation; financial 
market conditions; and future business decisions made by us and our 
competitors.  All of these factors are difficult or impossible to predict 
accurately and many of them are beyond our control.  For a further list and 
description of these and other important risks and uncertainties that may 
affect our future operations, see Part I, Item 1A - Risk Factors in our most 
recent Annual Report on Form 10-K filed with the Securities and Exchange 
Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly 
Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any 
intention or obligation to publicly update or revise any forward-looking 
statements to reflect any change in our expectations or in events, conditions 
or circumstances on which those expectations may be based, or that may affect 
the likelihood that actual results will differ from those contained in the 
forward-looking statements.  This cautionary statement is applicable to all 
forward-looking statements contained in this document.

CONTACTS:

Francesca Cardarelli
Media Relations, EMEA
+39 340 662 6364
Francesca.Cardarelli@bsci.com

Kirsten Lesak-Greenberg
Media Relations, U.S.
+1 (763) 300-9254
Kirsten.Lesak-Greenberg@bsci.com 

Susie Lisa, CFA
Investor Relations
+1 (508) 683-5670 
BSXInvestorRelations@bsci.com

(i) Data on file at Boston Scientific Corporation. Market research is as of 
2019 and includes projections for 2020, incorporating estimates for the 
COVID-19 pandemic. 
(ii) Mehta A, Muscarella L. Bronchoscope-related "superbug" infections. CHEST 
Journal. 2019; 157(2). DOI:https://doi.org/10.1016/j.chest.2019.08.003
(iii) Beilenhoff Ulrike et al. Reprocessing in GI endoscopy: ESGE-ESGENA 
Position Statement - Update 2018, Endoscopy 2018; 50

SOURCE: Boston Scientific Corporation